2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|March 2, 2003
- Pharmaceutical Technology-03-02-2003
- Volume 27
- Issue 3
A Review of Classification of Emerging Excipients in Parenteral Medications
Author(s)Shireesh P. Apte, PhD
As parenteral drug delivery becomes more complex and sophisticated, excipients that can facilitate drug (or gene) delivery to specific therapeutic targets will be required. An overwhelming majority of these excipients are derived from natural sources.
Advertisement
Articles in this issue
over 23 years ago
The Clarification of Bioreactor Cell Cultures for Biopharmaceuticalsover 23 years ago
Standards for Supplementsover 23 years ago
Concept Paper Discusses Update of Aspetic Processing Guidelinesover 23 years ago
Outsourcing Outlook March 2003over 23 years ago
March 2003Advertisement
Related to this article
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
Christy Owings, Thermo Fisher, on how AI complements clinical supply chain expertise, streamlines site logistics, and tracks shifting biotech markets.
Christy Owings, Thermo Fisher, speaks on why importer of record strategy and vetted local partners are key to reliable clinical trial supply chains.
Advertisement
Advertisement